CIDE-A Inhibitors
CIDE-A inhibitors belong to a specific chemical class characterized by their ability to modulate a key cellular process related to lipid metabolism and cellular homeostasis. These inhibitors interact with and target the cellular protein known as Cell Death-Inducing DFFA-like Effector A (CIDE-A). CIDE-A is a member of the CIDE family of proteins, which are predominantly found in the lipid droplets and play a crucial role in regulating lipid storage, lipid droplet morphology, and lipid-related cellular processes. CIDE-A is known to be involved in various cellular pathways that influence lipid metabolism, including apoptosis and lipid droplet fusion. CIDE-A inhibitors are designed to bind to the active site or specific binding sites of the CIDE-A protein, thereby modulating its activity. By doing so, these inhibitors can potentially impact the cellular processes that CIDE-A is associated with. The molecular structure of CIDE-A inhibitors is thought to be integral to their ability to interact with the protein in a precise manner, influencing its function. The inhibition of CIDE-A by these compounds may lead to altered lipid storage dynamics within cells, affecting lipid droplet growth, lipid utilization, and potentially cellular responses to various physiological and environmental cues.
Researchers have been exploring CIDE-A inhibitors as valuable tools to dissect the complex pathways involved in lipid metabolism and lipid-related disorders. Understanding the mechanisms by which these inhibitors interact with CIDE-A can shed light on the broader cellular processes in which CIDE-A is involved. This knowledge could have implications for various fields, including cellular biology and potentially even metabolic diseases. As research in this area continues to evolve, the detailed exploration of CIDE-A inhibitors may uncover novel insights into cellular lipid regulation and open up new avenues for understanding cellular health and function. In summary, CIDE-A inhibitors represent a distinctive class of compounds that interact with the CIDE-A protein to modulate its function and potentially impact lipid metabolism and cellular processes. Through their selective binding to CIDE-A, these inhibitors offer a valuable tool for researchers to investigate the intricate roles of CIDE-A in cellular biology, potentially contributing to advancements in our understanding of lipid-related processes and associated disorders.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Fluoxetine | 54910-89-3 | sc-279166 | 500 mg | $318.00 | 9 | |
Fluoxetine directly inhibits CIDE-A by interfering with its interaction with target molecules, reducing the enzyme's ability to facilitate cell death processes. This inhibition is achieved through Fluoxetine's action on the cellular localization of CIDE-A, limiting its function in apoptotic signaling pathways. | ||||||
Fluvoxamine | 54739-18-3 | sc-207697 | 25 mg | $321.00 | 1 | |
Fluvoxamine inhibits CIDE-A by altering the enzyme's conformation, which decreases its affinity for lipid substrates involved in the execution phase of apoptosis. This effect is mediated through Fluvoxamine's interaction with the regulatory domains of CIDE-A. | ||||||
Cimetidine | 51481-61-9 | sc-202996 sc-202996A | 5 g 10 g | $62.00 $86.00 | 1 | |
Cimetidine acts as an inhibitor of CIDE-A by competitively binding to the active site of the enzyme, preventing its participation in the cleavage of cellular components critical for apoptosis. This inhibition impacts the enzyme's role in programmed cell death. | ||||||
Omeprazole | 73590-58-6 | sc-202265 | 50 mg | $67.00 | 4 | |
(S)-Omeprazole Sodium Salt inhibits CIDE-A by disrupting the enzyme's ability to bind to its lipid substrates, essential for the propagation of apoptotic signals within the cell. This disruption is attributed to Esomeprazole's influence on the lipid environment where CIDE-A operates. | ||||||
Rabeprazole | 117976-89-3 | sc-204872 sc-204872A | 10 mg 25 mg | $349.00 $620.00 | 2 | |
Rabeprazole inhibits CIDE-A activity by modulating the enzyme's interaction with its co-factors, which are necessary for the execution of its apoptotic function. This modulation affects the enzyme's efficiency in promoting cell death. | ||||||
Fluconazole | 86386-73-4 | sc-205698 sc-205698A | 500 mg 1 g | $54.00 $84.00 | 14 | |
Fluconazole inhibits CIDE-A by interfering with its enzymatic activity, specifically targeting the enzyme's role in dismantling cellular structures during apoptosis. This interference is achieved through Fluconazole's binding to key regions of CIDE-A that are involved in substrate recognition. | ||||||
Propranolol | 525-66-6 | sc-507425 | 100 mg | $180.00 | ||
Propranolol inhibits CIDE-A by reducing the enzyme's catalytic activity, specifically targeting its role in the degradation of cellular components necessary for maintaining cell survival. This reduction is mediated through Propranolol's effects on the structural integrity of CIDE-A. | ||||||
Lansoprazole | 103577-45-3 | sc-203101 sc-203101A | 500 mg 1 g | $59.00 $176.00 | 6 | |
Lansoprazole inhibits CIDE-A by impairing the enzyme's ability to interact with its substrates, crucial for the initiation of the apoptotic process. This impairment is achieved by altering the electrostatic surface potential of CIDE-A, affecting substrate binding. | ||||||